Master Pharm Blog

A complete guide to weight loss peptides — how GLP-1 medicines work, which compounds clinics use, and how to understand Semaglutide, Tirzepatide, and Retatrutide.

Understand Semaglutide mechanism, expected outcomes, available formats (vial, pen, capsule, drops), and what clinics should explain to patients.

Learn how Tirzepatide's dual GIP/GLP-1 action differs from Semaglutide and when clinics include it in advanced weight management formularies.

What clinics and patients should understand about Retatrutide — the triple GLP-1/GIP/glucagon agonist for advanced metabolic programs.

A clear comparison of single-pathway GLP-1 medicines and dual GIP/GLP-1 agonists to help clinics and patients choose the right approach.

Non-injection options for weight management — Semaglutide capsules, Orforglipron, and sublingual drops explained for clinics and patients.

What clinics should know about Orforglipron capsules — a non-injection GLP-1 pathway option with multiple strength tiers for titration.

A practical decision guide — matching Semaglutide, Tirzepatide, Retatrutide, oral capsules, and drops to your patient population and program model.

How combination GLP and peptide blends fit within specialized clinic protocols for metabolic and recovery-focused programs.

Forecasting GLP and peptide demand, setting par levels, and streamlining reorder workflows for busy practices.

Structured consent, expectation setting, adherence coaching, and follow-up scripts that improve GLP program retention.

SKU selection, starter vs advanced pathways, oral alternatives, and wholesale planning for new metabolic health programs.

Refrigeration workflows, reconstitution hygiene, and inventory controls that protect peptide product quality.

Temperature, light exposure, beyond-use dating, and inventory rotation — essential storage practices for GLP vial formularies.

Understanding BPC-157 positioning within peptide therapy offerings — patient education, protocol structure, and formulary integration.

How oral Semaglutide capsules and sublingual drops expand non-injection pathways within supervised weight management programs.

Compare GLP-1 pen devices and multi-dose vials to optimize workflow, patient experience, and formulary efficiency.

What clinic teams should know about triple GLP-1/GIP/glucagon agonist therapy — patient selection, oversight, and formulary positioning.

A practical comparison of dual GIP/GLP-1 and GLP-1-only pathways to help clinics align formulary choices with patient profiles.

How clinics integrate Semaglutide vials into supervised weight management programs — dosing frameworks, patient selection, and supply planning.